Tavolixizumab is an investigational monoclonal antibody targeting the OX40 receptor, a protein involved in the regulation of immune responses. By binding to OX40, this antibody modulates T-cell activation, enhancing anti-tumor immunity. It is primarily being explored in oncology for the treatment of solid tumors and hematologic malignancies. The agent works by promoting the expansion and function of effector T cells while suppressing regulatory T cell activity, thereby shifting the tumor microenvironment toward immune activation. Clinical trials are evaluating its use both as a monotherapy and in combination with other immunotherapies such as checkpoint inhibitors to improve response rates in cancers resistant to current treatments. Its application represents a strategy to enhance adaptive immune responses in cancer immunotherapy.